Form 4: Vivani Medical Director Receives Annual Stock Option Grant

Vivani Medical, Inc. Director Wilford Dean Baker was granted 35,135 non-qualified stock options at an exercise price of $1.27 as part of the company's non-employee director compensation policy.

Summary

• Wilford Dean Baker, a Director of Vivani Medical, Inc. (VANI), acquired 35,135 non-qualified stock options.
• The transaction occurred on June 24, 2025.
• The exercise price for these options is $1.27 per share.
• These options were granted as part of the Issuer's Non-Employee Director Compensation Policy.
• The options will vest in full on the earlier of the first anniversary of the grant date (June 24, 2026) or the next annual meeting of stockholders, subject to continued service through such date.
• The options have an expiration date of June 23, 2035.
• Following this transaction, Mr. Baker beneficially owns 35,135 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of an equity grant to a director, which is a positive for aligning interests but does not contain significant new financial or operational news to dramatically shift sentiment. It's a standard, expected corporate action.

Positives

• The grant of stock options aligns with the company's established Non-Employee Director Compensation Policy, indicating consistent corporate governance practices.
• The options incentivize the director, Wilford Dean Baker, to contribute to the long-term success and share price appreciation of Vivani Medical, Inc.

Risks

• The value of the stock options is dependent on the future performance of Vivani Medical, Inc.'s common stock; if the stock price does not exceed the exercise price of $1.27, the options may expire worthless.
• The vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The grant of these stock options, vesting over time, indicates an expectation of continued service from the director and aligns their long-term interests with the company's future performance.

Management Comments

• The options were an annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.

Industry Context

This is a routine insider transaction (Form 4) reporting an equity grant to a director, common practice across industries to align director incentives with shareholder value. It does not provide specific insights into broader industry trends but reflects standard corporate governance for publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in publicly traded companies across various sectors, including the medical and biotechnology industries.
• The specific exercise price of $1.27 and the number of options (35,135) would typically be benchmarked against peer companies of similar market capitalization and stage of development, though no specific comparable companies, projects, or results are mentioned in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing stock price appreciation.
• Director (Wilford Dean Baker): Receives a significant equity stake, providing a direct financial incentive tied to the company's performance.

Next Steps

• The options will vest on the earlier of the first anniversary of the grant (June 24, 2026) or the next annual meeting of stockholders, subject to continued service.
• The director may exercise these options at any time after vesting and before the expiration date of June 23, 2035.

Key Dates

Keywords

Vivani Medical, VANI, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Non-Qualified Stock Option